Deregulation of microRNA expression in follicular cell-derived human thyroid carcinomas

Endocrine-Related Cancer

Volumn 17, Issue 1, 2010, Pages

  Pallante, Pierlorenzo ^a,b   Visone, Rosa ^a   Croce, Carlo Maria ^c   Fusco, Alfredo ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

CANCER DIAGNOSIS; CARCINOGENESIS; DEREGULATION; DOWN REGULATION; GENE CLUSTER; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HEREDITY; HUMAN; OVARY FOLLICLE CELL; REVIEW; THYROID CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ANIMALS; CARCINOMA; CARCINOMA, PAPILLARY; CELL TRANSFORMATION, NEOPLASTIC; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, TRANSGENIC; MICRORNAS; MUTATION; NEOPLASMS, RADIATION-INDUCED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; RNA, NEOPLASM; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77449090115     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0217     Document Type: Review

References (106)

1. Ain KB 1999 Anaplastic thyroid carcinoma: a therapeutic challenge. Seminars in Surgical Oncology 16 64-69.
2. Ambros V 2004 The functions of animal microRNAs. Nature 431 350-355.
3. Argraves WS, Greene LM, Cooley MA & Gallagher WM 2003 Fibulins: physiological and disease perspectives. EMBO Reports 4 1127-1131.
4. Baldassarre G, Belletti B, Bruni P, Boccia A, Trapasso F, Pentimalli F, Barone MV, Chiappetta G, Vento MT, Spiezia S et al. 1999 Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. Journal of Clinical Investigation 104 865-874.
5. Bartel DP 2004 MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 281-297.
6. Basolo F, Pisaturo F, Pollina LE, Fontanini G, Elisei R, Molinaro E, Iacconi P, Miccoli P & Pacini F 2000 N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 10 19-23.
7. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J & Benz CC 2008 Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 27 5643-5647.
8. Biunno I, Cattaneo M, Orlandi R, Canton C, Biagiotti L, Ferrero S, Barberis M, Pupa SM, Scarpa A & Ménard S 2006 SEL1L a multifaceted protein playing a role in tumor progression. Journal of Cellular Physiology 208 23-38.
9. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A & Springer TA 1996 A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). Journal of Experimental Medicine 184 1101-1109.
10. Boucheix C, Duc GH, Jasmin C & Rubinstein E 2001 Tetraspanins and malignancy. Expert Reviews in Molecular Medicine 2001 1-17.
11. Calin GA & Croce CM 2006 MicroRNA signatures in human cancers. Nature Reviews. Cancer 6 857-866.
12. Carcangiu ML, Zampi G & Rosai J 1984 Poorly differentiated ("insular") thyroid carcinoma. A reinterpretation of Langhans' "wuchernde Struma". American Journal of Surgical Pathology 8 655-668.
13. Carraro G, El-Hashash A, Guidolin D, Tiozzo C, Turcatel G, Young BM, De Langhe SP, Bellusci S, Shi W, Parnigotto PP et al. 2009 miR-17 family of microRNAs controls FGF10-mediated embryonic lung epithelial branching morphogenesis through MAPK14 and STAT3 regulation of E-cadherin distribution. Developmental Biology 333 238-250.
14. Castellone MD, Guarino V, De Falco V, Carlomagno F, Basolo F, Faviana P, Kruhoffer M, Orntoft T, Russell JP, Rothstein JL et al. 2004 Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene 23 5958-5967.
15. Chen J, Jackson PK, Kirschner MW& Dutta A 1995 Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374 386-388.
16. Chen YT, Kitabayashi N, Zhou XK, Fahey TJ III & Scognamiglio T 2008 MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Modern Pathology 21 1139-1146.
17. Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM & Farace MG 2005 Extensive modulation of a set of microRNAs in primary glioblastoma. Biochemical and Biophysical Research Communications 334 1351-1358.
18. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA & Nikiforov YE 2005 Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. Journal of Clinical Investigation 115 94-101.
19. DeLellis RA, Lloyd RV, Heitz PU & Eng C 2004 Thyroid and parathyroid tumours. In World Health Organization. Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. pp 51-56. Lyon, France: IARC Press.
20. Dhillon AS & Kolch W 2004 Oncogenic B-Raf mutations: crystal clear at last. Cancer Cell 5 303-304.
21. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G & Pierotti MA 1993 Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. Journal of Clinical Investigation 91 1753-1760.
22. Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G, Höög A, Frisk T, Larsson C & Zedenius J 2003 Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. Journal of Clinical Endocrinology and Metabolism 88 4440-4445.
23. Elmén J, Lindow M, Schütz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjärn M, Hansen HF, Berger U et al. 2008 LNA-mediated microRNA silencing in non-human primates. Nature 452 896-899.
24. Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW & Harris PE 1999 Prevalence of Ras mutations in thyroid neoplasia. Clinical Endocrinology 50 529-535.
25. Ezzat S, Zheng L, Kolenda J, Safarian A, Freeman JL & Asa SL 1996 Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid 6 409-416.
26. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH & Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. Journal of Clinical Investigation 91 179-184.
27. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, Liuzzi F, Lulli V, Morsilli O, Santoro S et al. 2005 MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. PNAS 102 18081-18086.
28. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM, Bolondi L et al. 2008 MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 27 5651-5661.
29. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S et al. 2004 Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23 7436-7440.
30. French CA, Alexander EK, Cibas ES, Nose V, Laguette J, Faquin W, Garber J, Moore F Jr, Fletcher JA, Larsen PR et al. 2003 Genetic and biological subgroups of low-stage follicular thyroid cancer. American Journal of Pathology 162 1053-1060.
31. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA & Farace MG 2007 miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. Journal of Biological Chemistry 282 23716-23724.
32. Gallagher WM, Greene LM, Ryan MP, Sierra V, Berger A, Laurent-Puig P & Conseiller E 2001 Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues. FEBS Letters 489 59-66.
33. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL & Tallini G 2001 Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. American Journal of Pathology 158 987-996.
34. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J & Santoro M 2005 Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Research 65 10199-10207.
35. Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, Liu CG, Croce CM & Condorelli G 2008 MicroRNA signatures of TRAIL resistance in human nonsmall cell lung cancer. Oncogene 27 3845-3855.
36. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A & Vecchio G 1990 PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60 557-563.
37. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A & Enright AJ 2006 miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Research 34 D140-D144.
38. Griffiths-Jones S, Saini HK, van Dongen S & Enright AJ 2008 miRBase: tools for microRNA genomics. Nucleic Acids Research 36 D154-D158.
39. Gu Y, Turck CW & Morgan DO 1993 Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366 707-710.
40. Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG & Xiong Y 1994 Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2- related CDK6 inhibitor, correlates with wild-type pRb function. Genes and Development 8 2939-2952.
41. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Sigurdsson A, Bergthorsson JT, He H, Blondal T, Geller F, Jakobsdottir M et al. 2009 Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nature Genetics 41 460-464.
42. Hannon GJ, Casso D & Beach D 1994 KAP: a dual specificity phosphatase that interacts with cyclin-dependent kinases. PNAS 91 1731-1735.
43. Harach HR, Escalante DA & Day ES 2002 Thyroid cancer and thyroiditis in Salta, Argentina: a 40-yr study in relation to iodine prophylaxis. Endocrine Pathology 13 175-181.
44. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S et al. 2005 The role of microRNA genes in papillary thyroid carcinoma. PNAS 102 19075-19080.
45. Henson BJ, Bhattacharjee S, O'Dee DM, Feingold E & Gollin SM 2009 Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. Genes, Chromosomes & Cancer 48 569-582.
46. Hirai H, Roussel MF, Kato JY, Ashmun RA & Sherr CJ 1995 Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Molecular and Cellular Biology 15 2672-2681.
47. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G et al. 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clinical Cancer Research 13 1161-1170.
48. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS & Welch DR 2009 Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Research 69 1279-1283.
49. ItoT, SeyamaT, Mizuno T, TsuyamaN,Hayashi T, HayashiY, Dohi K, Nakamura N & Akiyama M 1992 Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Research 52 1369-1371.
50. Ito Y, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K & Miyauchi A 2005 Telomerase activity in thyroid neoplasms evaluated by the expression of human telomerase reverse transcriptase (hTERT). Anticancer Research 25 509-514.
51. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR & de la Chapelle A 2008 Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. PNAS 105 7269-7274.
52. Jazdzewski K, Liyanarachchi S, Swierniak M, Pachucki J, Ringel MD, Jarzab B & de la Chapelle A 2009 Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. PNAS 106 1502-1505.
53. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T & Thun MJ 2008 Cancer statistics, 2008. CA: A Cancer Journal for Clinicians 58 71-96.
54. Kaldis P 2007 Another piece of the p27Kip1 puzzle. Cell 128 241-244.
55. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE & Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research 63 1454-1457.
56. Kondo T, Ezzat S & Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews. Cancer 6 292-306.
57. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR et al. 2009 Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137 1005-1017.
58. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM & Fletcher JA 2000 PAX8-PPAR-gamma1 fusion oncogene in human thyroid carcinoma. Science 289 1357-1360.
59. Labbaye C, Spinello I, Quaranta MT, Pelosi E, Pasquini L, Petrucci E, Biffoni M, Nuzzolo ER, Billi M, Foà R et al. 2008 A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nature Cell Biology 10 788-801.
60. Ledent C, Dumont J, Vassart G & Parmentier M 1991 Thyroid adenocarcinomas secondary to tissue-specific expression of simian virus-40 large T-antigen in transgenic mice. Endocrinology 129 1391-1401.
61. Lindor NM & Greene MH 1998 The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. Journal of the National Cancer Institute 90 1039-1071.
62. Liu X, Yu J, Jiang L, Wang A, Shi F, Ye H & Zhou X 2009 MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics & Proteomics 6 131-139.
63. LiVolsi VA & Asa SL 1994 The demise of follicular carcinoma of the thyroid gland. Thyroid: Official Journal of the American Thyroid Association 4 233-236.
64. Lupoli G, Vitale G, Caraglia M, Fittipaldi MR, Abbruzzese A, Tagliaferri P&Bianco AR 1999 Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet 353 637-639.
65. McCall KD, Harii N, Lewis CJ, Malgor R, Kim WB, Saji M, Kohn AD, Moon RT & Kohn LD 2007 High basal levels of functional toll-like receptor 3 (TLR3) and noncanonical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology 148 4226-4237.
66. Mitomo S, Maesawa C, Ogasawara S, Iwaya T, Shibazaki M, Yashima-Abo A, Kotani K, Oikawa H, Sakurai E, Izutsu N et al. 2008 Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Science 99 280-286.
67. Miyake N, Maeta H, Horie S, Kitamura Y, Nanba E, Kobayashi K & Terada T 2001 Absence of mutations in the beta-catenin and adenomatous polyposis coli genes in papillary and follicular thyroid carcinomas. Pathology International 51 680-685.
68. Motoi N, Sakamoto A, Yamochi T, Horiuchi H, Motoi T & Machinami R 2000 Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathology, Research and Practice 196 1-7.
69. Namba H, Rubin SA & Fagin JA 1990 Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Molecular Endocrinology 4 1474-1479.
70. Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST & Ghoshal K 2008 Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. Journal of Biological Chemistry 283 33394-33405.
71. Natali PG, Berlingieri MT, Nicotra MR, Fusco A, Santoro E, Bigotti A & Vecchio G 1995 Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Research 55 1787-1791.
72. Nikiforov YE 2002 RET/PTC rearrangement in thyroid tumors. Endocrine Pathology 13 3-16.
73. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW II, Tallini G, Kroll TG & Nikiforov YE 2003 RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. Journal of Clinical Endocrinology and Metabolism 88 2318-2326.
74. Nikiforova MN, Tseng GC, Steward D, Diorio D & Nikiforov YE 2008 MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. Journal of Clinical Endocrinology and Metabolism 93 1600-1608.
75. Ozen M, Creighton CJ, Ozdemir M & Ittmann M 2008 Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27 1788-1793.
76. Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, Chiappetta G, Terrazzano G, Liguoro D, Vito P et al. 2004 Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. Journal of Biological Chemistry 279 54610-54619.
77. Paes JE & Ringel MD 2008 Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinology and Metabolism Clinics of North America 37 375-387.
78. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, Chiappetta G, Liu CG, Santoro M, Negrini M et al. 2006 MicroRNA deregulation in human thyroid papillary carcinomas. Endocrine-Related Cancer 13 497-508.
79. Pierotti MA, Bongarzone I, Borrello MG, Mariani C, Miranda C, Sozzi G & Greco A 1995 Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas. Journal of Endocrinological Investigation 18 130-133.
80. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P & Massagué J 1994 Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78 59-66.
81. Rhoades MW, Reinhart BJ, Lim LP, Burge CB, Bartel B & Bartel DP 2002 Prediction of plant microRNA targets. Cell 110 513-520.
82. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM et al. 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Research 69 4885-4893.
83. Santarpia L, El-Naggar AK, Cote GJ, Myers JN & Sherman SI 2008 Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. Journal of Clinical Endocrinology and Metabolism 93 278-284.
84. Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G & Fusco A 1994 Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 9 509-516.
85. Santoro M, Papotti M, Chiappetta G, Garcia-Rostan G, Volante M, Johnson C, Camp RL, Pentimalli F, Monaco C, HerreroAet al. 2002RET activation and clinicopathologic features in poorly differentiated thyroid tumors. Journal of Clinical Endocrinology and Metabolism 87 370-379.
86. Santoro M, Carlomagno F, Melillo RM & Fusco A 2004 Dysfunction of the RET receptor in human cancer. Cellular and Molecular Life Sciences 61 2954-2964.
87. Schulte KM, Jonas C, Krebs R & Roher HD 2000 Activin A and activin receptors in the human thyroid: a link to the female predominance of goiter? Hormone and Metabolic Research 32 390-400.
88. Schulte KM, Jonas C, Krebs R & Roher HD 2001 Activin A and activin receptors in thyroid cancer. Thyroid 11 3-14.
89. Schwertheim S, Sheu SY, Worm K, Grabellus F & Schmid KW 2009 Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Hormone and Metabolic Research 41 475-481.
90. Serrano M, Hannon GJ & Beach D 1993 A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366 704-707.
91. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Máximo V, Botelho T, Seruca R & Sobrinho-Simões M 2003 BRAF rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22 4578-4580.
92. Suarez HG, du Villard JA, Severino M, Caillou B, Schlumberger M, Tubiana M, Parmentier C & Monier R 1990 Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 5 565-570.
93. Taganov KD, Boldin MP, Chang KJ & Baltimore D 2006 NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. PNAS 103 12481-12486.
94. Taganov KD, Boldin MP & Baltimore D 2007 MicroRNAs and immunity: tiny players in a big field. Immunity 26 133-137.
95. Takakura S, Mitsutake N, Nakashima M, Namba H, Saenko VA, Rogounovitch TI, Nakazawa Y, Hayashi T, Ohtsuru A & Yamashita S 2008 Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Science 99 1147-1154.
96. Tang G, Reinhart BJ, Bartel DP & Zamore PD 2003 A biochemical framework for RNA silencing in plants. Genes and development 17 49-63.
97. Tetzlaff MT, Liu A, Xu X, Master SR, Baldwin DA, Tobias JW, Livolsi VA & Baloch ZW 2007 Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocrine Pathology 18 163-173.
98. Vasko VV, Gaudart J, Allasia C, Savchenko V, Di Cristofaro J, Saji M, Ringel MD & De Micco C 2004 Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma. European Journal of Endocrinology 151 779-786.
99. Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K, Miano MP, de Nigris F, Casalino L, Curcio F et al. 1997 Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 15 1987-1994.
100. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM et al. 2007a MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocrine-Related Cancer 14 791-798.
101. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E et al. 2007b Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26 7590-7595.
102. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M et al. 2006 A microRNA expression signature of human solid tumors defines cancer gene targets. PNAS 103 2257-2261.
103. Weber F, Teresi RE, Broelsch CE, Frilling A & Eng C 2006 A limited set of human microRNA is deregulated in follicular thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 91 3584-3591.
104. Williams D 2002 Cancer after nuclear fallout: lessons from the Chernobyl accident. Nature Reviews. Cancer 2 543-549.
105. Yau T, Lo CY, Epstein RJ, Lam AK, Wan KY & Lang BH 2008 Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy. Annals of Surgical Oncology 15 2500-2505.
106. Zhu H, Wu H, Liu X, Li B, Chen Y, Ren X, Liu CG & Yang JM 2009 Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. Autophagy 5 816-823.